<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001504</url>
  </required_header>
  <id_info>
    <org_study_id>960080</org_study_id>
    <secondary_id>96-C-0080</secondary_id>
    <nct_id>NCT00001504</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients</brief_title>
  <official_title>A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic&#xD;
      acid given in combination with tamoxifen. Groups of 3 to 6 patients receive oral&#xD;
      9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the&#xD;
      regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the&#xD;
      study if medically appropriate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I study of the combination tamoxifen and 9-cis-Retinoic acid in patients with&#xD;
      breast cancer. The primary objective of the study is; 1) to determine the maximum tolerated&#xD;
      dose of 9-cis-Retinoic acid in combination with Tamoxifen and to determine the overall and&#xD;
      dose limiting toxicities. Other objectives are: 2) to determine the effect of Tamoxifen on&#xD;
      the pharmacokinetics of 9-cis-Retinoic acid; 3) to evaluate the anti-tumor activity of this&#xD;
      combination therapy within the context of a phase I study; 4) and to determine the expression&#xD;
      of surrogate biomarkers of breast carcinogenesis before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date>January 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>18</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>9-cis-Retinoic Acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        All patients must have histologically documented diagnosis of Stage III, or IV breast&#xD;
        carcinoma.&#xD;
&#xD;
        Patients with stage III that has completed chemotherapy: Estrogen receptor (ER) or&#xD;
        progesterone receptor (PR) positive tumor required if premenopausal. Either ER/PR-positive&#xD;
        or -negative tumor allowed if postmenopausal and have received prior chemotherapy.&#xD;
&#xD;
        Patients may have stage IV with ER/PR-positive or -negative tumor.&#xD;
&#xD;
        No CNS metastases, pseudotumor cereri, or seizures.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Patients who have ecovered from the toxic effects of prior therapy will be eligible.&#xD;
&#xD;
        Patients with prior tamoxifen will be allowed to participate. At least 3 weeks must have&#xD;
        elapsed since the last dose of chemotherapy.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Sex: Men and women.&#xD;
&#xD;
        Menopausal status: Any status.&#xD;
&#xD;
        Patients must have a performance status of ECOG 0-2.&#xD;
&#xD;
        Patients must have Hematopoietic criteria of:&#xD;
&#xD;
        ANC at least 1,500/mm(3).&#xD;
&#xD;
        Platelet count at least 90,000/mm(3).&#xD;
&#xD;
        Patients must have Hepatic criteria of:&#xD;
&#xD;
        In the absence of tumor involvement:&#xD;
&#xD;
        Bilirubin no greater than twice normal;&#xD;
&#xD;
        SGOT no greater than twice normal;&#xD;
&#xD;
        Alkaline phosphate no greater than twice normal;&#xD;
&#xD;
        Fasting triglycerides less than 3 times normal.&#xD;
&#xD;
        Patients must have Renal criteria of:&#xD;
&#xD;
        Serum creatinine no greater than 1.5 mg/dL OR;&#xD;
&#xD;
        Creatinine clearance at least 60 mL/min.&#xD;
&#xD;
        Other:&#xD;
&#xD;
        No allergy to study medications.&#xD;
&#xD;
        No nonmalignant systemic disease that would preclude therapy.&#xD;
&#xD;
        No second malignancy within 5 years except: Curatively treated basal cell skin carcinoma.&#xD;
        Cervical carcinoma in situ.&#xD;
&#xD;
        Pregnant women will be excluded.&#xD;
&#xD;
        Negative pregnancy test required within 7 days prior to entry.&#xD;
&#xD;
        Adequate contraception required for 4 weeks prior to, during, and for 1 year after study.&#xD;
&#xD;
        Patients must give informed consent.&#xD;
&#xD;
        Patients who are poor medical or psychiatric risks will be eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fontana JA. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol. 1987;55(3):136-44. doi: 10.1159/000163409.</citation>
    <PMID>3666278</PMID>
  </reference>
  <reference>
    <citation>Welsch CW, DeHoog JV. Retinoid feeding, hormone inhibition, and/or immune stimulation and the genesis of carcinogen-induced rat mammary carcinomas. Cancer Res. 1983 Feb;43(2):585-91.</citation>
    <PMID>6401220</PMID>
  </reference>
  <reference>
    <citation>Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev. 1990 Nov;11(4):578-610. doi: 10.1210/edrv-11-4-578. No abstract available.</citation>
    <PMID>2292243</PMID>
  </reference>
  <verification_date>January 2002</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Retinoids</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Alitretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

